Wnt pathway stimulation in reprogramming somatic cells with nuclear reprogramming factors

Patent metadata

Field	Value
Publication number	US-9593311-B2
Application number	US-201514822653-A
Country	US
Kind code	B2
Filing date	Aug 10, 2015
Priority date	Aug 31, 2007
Publication date	Mar 14, 2017
Grant date	Mar 14, 2017

Abstract

The invention provides compositions and methods of use in reprogramming somatic cells. Compositions and methods of the invention are of use, e.g., for generating or modulating (e.g., enhancing) generation of induced pluripotent stem cells by reprogramming somatic cells. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a pluripotent state and/or enhances the speed and/or efficiency of reprogramming. Certain of the compositions and methods relate to modulating the Wnt pathway.

First claim

The invention claimed is:

1. A method of reprogramming a mammalian somatic cell, comprising:
(a) introducing into the mammalian somatic cell, one or more retroviral vectors encoding Oct4, and optionally encoding one or more reprogramming factors selected from the group consisting of: Klf4 and Sox2, wherein c-Myc is not introduced into the cell;
(b) contacting the mammalian somatic cell with a Wnt-3a conditioned medium; or an agent that modulates the Wnt pathway selected from the group consisting of a recombinant, exogenous, soluble, and biologically active Wnt protein, and a GSK-3 antagonist; and
(c) culturing the cells under conditions suitable for reprogramming the mammalian somatic cell to a pluripotent state.

2. The method of claim 1 , wherein the method comprises: (a) culturing the cell in culture medium containing the agent; (b) culturing the cell in culture medium comprising the Wnt-3 a conditioned medium or the agent for at least 10 days; (c) contacting the cell with the Wnt-3a conditioned medium or the agent that modulates the Wnt pathway, thereby enhancing the number of ES-like cell colonies by at least 5-fold; (d) contacting the cell with the Wnt-3a conditioned medium or the agent that modulates the Wnt pathway, thereby enhancing the number of ES-like cell colonies by at least 10-fold; (e) culturing the cell in the Wnt3a-conditioned medium; (f) contacting the cell with a second agent that modulates the Wnt pathway; or (g) culturing the cell in medium containing the recombinant, exogenous, soluble, and biologically active Wnt protein.

3. The method of claim 1 , wherein the cell: (a) is a human cell; (b) is a terminally differentiated cell; (c) is a fibroblast; or (d) is modified to express or contain at least one reprogramming factor at levels greater than normally present in cells of that type.

4. The method of claim 2 , wherein the recombinant, exogenous, soluble, and biologically active Wnt protein is Wnt3a.

5. The method of claim 1 , further comprising: (a) confirming that the reprogrammed cell is pluripotent; (b) administering the reprogrammed cell to a subject; or (c) differentiating the cell to a desired cell type in vitro after reprogramming the cell.

6. The method of claim 1 , wherein the method is practiced on: (a) a population of cells and the method further comprises identifying ES-like cells by morphological criteria; (b) a population of cells and the method does not comprise imposing chemical selection to select reprogrammed cells; or (c) a population of cells and the method further comprises separating cells that are reprogrammed to a pluripotent state from cells that are not reprogrammed to a pluripotent state.

7. A composition comprising:
(a) an iPS cell; and
(b) a Wnt-3 a conditioned medium; or an agent that increases activity of a Wnt pathway selected from the group consisting of a recombinant, exogenous, soluble, and biologically active Wnt protein, and a GSK-3 antagonist.

8. The composition of claim 7 , wherein the recombinant, exogenous, soluble, and biologically active Wnt protein is Wnt3a.

Assignees

• Whitehead Inst Biomedical Res

Inventors

• Chevalier Brett
• Marson Alexander
• Young Richard A
• Foreman Ruth
• Jaenisch Rudolf

Classifications

• A61P31/18

  for HIV · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61P35/02

  specific for leukemia · CPC title